Effectiveness of spironolactone on adult female acne: Critical practice
DOI:
https://doi.org/10.33448/rsd-v13i4.45557Keywords:
Acne Vulgaris; Spironolactone; Drug Prescriptions; Dermatology.Abstract
Introduction: Adult acne (AMA) is a growing concern due to its impact on self-esteem and skin aesthetics. This study investigated the effectiveness of spironolactone in the treatment of AMA. The present article aims to provide a comprehensive update of available treatments for acne, focusing on an emerging and promising therapeutic agent: spironolactone. Methodology: Terms such as "Acne and Spironolactone", "Woman and acne" and "Spironolactone and acne treatment" were used. Ten articles were selected, including clinical and observational studies of works published between 2017 and 2023, searched in the SciELO, PubMed, Google Scholar and VHL databases. Results and discussion: Spironolactone, initially indicated for other conditions, has promising effects in AMA due to its potential androgenic antagonism. Spironolactone is often used in combination with other treatments, and despite side effects, its tolerance is generally good. The average dosage used was 100 mg for six months, adjusted according to adverse effects. Multicenter studies have indicated a low risk of hyperkalemia with the use of spironolactone to treat AMA. Research has also highlighted spironolactone's ability to treat injuries in several areas, including the face and trunk. Conclusion: Spironolactone emerges as a promising therapeutic option for adult acne, despite limited scientific evidence. Its use has demonstrated effectiveness in controlling lesions, especially when associated with topical retinoids. It is crucial to monitor kidney function and potassium levels. Additional studies are needed to consolidate its role in the treatment of AMA and fully understand its effectiveness and safety.
References
Addor, F. A. S., & Schalka, S. (2010). Acne da mulher adulta: aspectos epidemiológicos, diagnósticos e terapêuticos. Anais Brasileiros De Dermatologia, 85(6), 789–795. https://doi.org/10.1590/S0365-05962010000600003
Bagatin, E., Freitas, T. H. P., Rivitti-Machado, M. C., Machado, M. C. R., Ribeiro, B. M., Nunes, S., & Rocha, M. A. D. D. (2019). Adult female acne: a guide to clinical practice. Anais brasileiros de dermatologia, 94(1), 62–75. https://doi.org/10.1590/abd1806-4841.20198203.
Barbieri, J. S., Spaccarelli, N., Margolis, D. J., & James, W. D. (2019). Approaches to limit systemic antibiotic use in acne: Systemic alternatives, emerging topical therapies, dietary modification, and laser and light-based treatments. Journal of the American Academy of Dermatology, 80(2), 538–549. https://doi.org/10.1016/j.jaad.2018.09.055
Barros, A. B. de, Sarruf, F. D., Fileto, M. B., & Robles Velasco, M. V. (2020). Acne vulgar: aspectos gerais e atualizações no protocolo de tratamento. BWS Journal, 3, 1–13. Recuperado de https://bwsjournal.emnuvens.com.br/bwsj/article/view/125
Bienenfeld, A., Azarchi, S., Lo Sicco, K., Marchbein, S., Shapiro, J., & Nagler, A. R. (2019). Androgens in women: Androgen-mediated skin disease and patient evaluation. Journal of the American Academy of Dermatology, 80(6), 1497–1506. https://doi.org/10.1016/j.jaad.2018.08.062
Brucker, M. C., & King, T. L. (2017). The 2015 US Food and Drug Administration Pregnancy and Lactation Labeling Rule. Journal of midwifery & women's health, 62(3), 308–316. https://doi.org/10.1111/jmwh.12611
Charny, J. W., Choi, J. K., & James, W. D. (2017). Spironolactone for the treatment of acne in women, a retrospective study of 110 patients. International journal of women's dermatology, 3(2), 111–115. https://doi.org/10.1016/j.ijwd.2016.12.002
Costa, A., Mota, M., & Cristina, M. (2008). Fatores etiopatogênicos da acne vulgar. Anais Brasileiros de Dermatologia, 83(5), 451–459. https://doi.org/10.1590/s0365-05962008000500010
Costa, C. S., & Bagatin, E. (2013). Evidence on acne therapy. São Paulo medical journal = Revista paulista de medicina, 131(3), 193–197. https://doi.org/10.1590/1516-3180.2013.1313616
Federman, D. G., & Kirsner, R. S. (2000). Acne vulgaris: pathogenesis and therapeutic approach. The American journal of managed care, 6(1), 78 89.
Goulden V, Stables GI, Cunliffe WJ. Prevalence of facial acne in adults. J Am Acad Dermatol. 1999 Oct;41(4):577-80. PMID: 10495379.
Goulden, V., Stables, G. I., & Cunliffe, W. J. (1999). Prevalence of facial acne in adults. Journal of the American Academy of Dermatology, 41(4), 577–580.
Grandhi, R., & Alikhan, A. (2017). Spironolactone for the Treatment of Acne: A 4-Year Retrospective Study. Dermatology (Basel, Switzerland), 233(2-3), 141–144. https://doi.org/10.1159/000471799
Ministério da Saúde. (2023). Retrieved November 15, 2023, from Saude.gov.br website: https://bvsms.saude.gov.br/bvs/saudelegis/anvisa/2010/res0060_17_12_2010.html
Plovanich, M., Weng, Q. Y., & Mostaghimi, A. (2015). Low Usefulness of Potassium Monitoring Among Healthy Young Women Taking Spironolactone for Acne. JAMA dermatology, 151(9), 941–944. https://doi.org/10.1001/jamadermatol.2015.34
Roberts, E. E., Nowsheen, S., Davis, M. D. P., McEvoy, M. T., Newman, C. C., Sartori Valinotti, J. C., Sciallis, G. F., Torgerson, R. R., & Wetter, D. A. (2020). Treatment of acne with spironolactone: a retrospective review of 395 adult patients at Mayo Clinic, 2007-2017. Journal of the European Academy of Dermatology and Venereology: JEADV, 34(9), 2106–2110. https://doi.org/10.1111/jdv.16302
Santer, M., & Layton, A. (2023). What do we know about prescribing spironolactone for acne? BMJ (Clinical research ed.), 381, 1114. https://doi.org/10.1136/bmj.p1114
Santer, M., Lawrence, M., Renz, S., Eminton, Z., Stuart, B., Sach, T. H., Pyne, S., Ridd, M. J., Francis, N., Soulsby, I., Thomas, K., Permyakova, N., Little, P., Muller, I., Nuttall, J., Griffiths, G., Thomas, K. S., Layton, A. M., & SAFA trial investigators (2023). Effectiveness of spironolactone for women with acne vulgaris (SAFA) in England and Wales: pragmatic, multicentre, phase 3, double blind, randomised controlled trial. BMJ (Clinical research ed.), 381, e074349. https://doi.org/10.1136/bmj-2022-074349
Silva, A. M. F. da, Costa, F. P. da, & Moreira, M. (2014). Acne vulgar: diagnóstico e manejo pelo médico de família e comunidade. Revista Brasileira De Medicina De Família E Comunidade, 9(30), 54–63. https://doi.org/10.5712/rbmfc9(30)754
Vargas-Mora, P., & Morgado-Carrasco, D. (2020). Spironolactone in Dermatology: Uses in Acne, Hidradenitis Suppurativa, Female Pattern Baldness, and Hirsutism. Uso de la espironolactona en dermatología: acné, hidradenitis supurativa, alopecia femenina e hirsutismo. Actas dermo-sifiliograficas, 111(8), 639–649. https://doi.org/10.1016/j.ad.2020.03.001
Vaz, A. L. (2003). ACNE vulgar: Bases para o seu tratamento. Revista Portuguesa De Medicina Geral E Familiar, 19(6), 561–70. https://doi.org/10.32385/rpmgf.v19i6.9989
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Ludmilla Pimentel Santos; Camila Zanetti Machado; Camilla Nunes Proença Formoso; Izabela Schneidewind; Juliana Silvares Gonçalves Canal; Guilherme Gomes Azizi
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
